Animal vaccine firm Virbac's Q1 revenue rises on North America performance

Virbac SA

16/04/2026 16:56

Overview

France animal health firm's Q1 2026 revenue rose 7.7% at constant rates, up 2.2% at actual rates

Growth driven by strong North America and International performance; companion animal segment up 9.9%

2026 guidance unchanged; expects 5.5%-7.5% revenue growth at constant rates, 17% adjusted operating margin

Outlook

Virbac expects 2026 revenue growth between 5.5% and 7.5% at constant rates and scope

Company sees 2026 adjusted operating income margin around 17%

Result Drivers

SUPERCHARGE PLATFORMS - Growth in key product platforms, including petfood, reproduction, dental, mobility, ear, endocrinology, and ruminants, contributed around +15% at constant rates and scope

NORTH AMERICA PERFORMANCE - Exceptional growth in North America, driven by Supercharge categories and the Thyronorm acquisition, offsetting some farm animal declines

VOLUME/MIX AND PRICING - Solid volume/mix effect of about +6%, complemented by price increases of about +2%

Company press release: ID:nGNE5rYz6Q

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 384 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Virbac SA is €412.00, about 14.3% above its April 15 closing price of €360.50

The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 17 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)